On August 31, JOINN fell 5.06% in regular trading, trading at HK$24.02/share, with turnover of approximately HK$75.38 million. The selloff followed the company's interim results released on August 28, which revealed a stark disconnect between headline earnings and underlying business quality.

JOINN reported H1 attributable net profit of RMB 748 million, surging 1,126.8% year-over-year, while revenue came in at RMB 704 million, up only 5.27%. The profit explosion was primarily driven by fair value gains on biological assets, which contributed approximately RMB 703–777 million in net profit. Stripping out this factor, the company's core laboratory services and other operations posted a net loss of RMB 36.61 million, underscoring persistent weakness in its primary business. Gross margin improved to 20.6% from 15.7%, and in-hand orders reached RMB 3.7 billion, up 60.9%, with new orders of RMB 2.02 billion, nearly doubling year-over-year.

The broader Life Sciences Tools and Services sector traded uniformly lower on the same day, amplifying selling pressure. WUXI BIO fell 5.39%, GENSCRIPT BIO dropped 5.43%, WUXI APPTEC declined 4.41%, WUXI XDC lost 4.43%, and INSILICO slid 6.78%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)